6/10/2010

U.S. regulators need to release improved guidelines and provide financial incentives covering antibiotics development so researchers and companies will be encouraged to develop new drugs, particularly as cases of drug-resistant bacteria are increasing, experts on Wednesday told the House Committee on Energy and Commerce's Subcommittee on Health. "FDA plans to publish additional guidance on these [drug development] methods within the next six months to establish new standards for antimicrobial drugs," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Full Story:
Reuters

Related Summaries